^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    SP140 (SP140 Nuclear Body Protein)

    i
    Other names: SP140, SP140 Nuclear Body Protein, LYSP100-B, LYSP100-A, Lymphoid-Restricted Homolog Of Sp100, Nuclear Body Protein SP140, Nuclear Autoantigen Sp-140, Speckled 140 KDa, LYSP100, Lymphoid-Specific SP100 Homolog, LYSp100
    2ms
    Transient SP140 inhibition unlocks hematopoietic stem cell fate from human pluripotent stem cells. (PubMed, Blood)
    Importantly, selective SP140 inhibition in a chemically defined, scalable protocol enabled rapid in vitro generation of bona fide human HSCs suitable for transplantation. These findings identify transient SP140 inhibition as an effective strategy to overcome epigenetic barriers and unlock clinically relevant HSC specification from hPSCs, advancing regenerative hematopoiesis and cell therapy.
    Journal
    |
    SP140 (SP140 Nuclear Body Protein)
    8ms
    Identification of protein-coding genes associated with metastatic prostate cancer. (PubMed, Endocr Relat Cancer)
    Furthermore, we confirmed the prognostic significance of TMEM18 expression at the protein level with immunohistochemistry (IHC) in a primary PCa tumor cohort. In conclusion, we identified 85 mCRPC-associated genes and showed that TMEM18 has prognostic value in early PCa.
    Journal
    |
    AR (Androgen receptor) • SP140 (SP140 Nuclear Body Protein) • FOXA1 (Forkhead Box A1) • TLE3 (TLE Family Member 3, Transcriptional Corepressor) • TP63 (Tumor protein 63) • JARID2 (Jumonji And AT-Rich Interaction Domain Containing 2) • HOXB13 (Homeobox B13) • SUZ12 (SUZ12 Polycomb Repressive Complex 2 Subunit) • CBX8 (Chromobox 8)
    1year
    High-Risk MCL: Recognition and Treatment. (PubMed, Blood)
    These findings necessitate revisiting the prognostic impact of high-risk factors, current management strategies, new bi- and tri-specific T-cell engagers, combination therapies, novel therapeutic targets, and next-generation clinical trials for high-risk MCL patients. This article provides a comprehensive update on recognizing and managing high-risk MCL, encompassing current practices and future directions.
    Journal
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • NOTCH2 (Notch 2) • BIRC3 (Baculoviral IAP repeat containing 3) • CD70 (CD70 Molecule) • SP140 (SP140 Nuclear Body Protein) • MSI2 (Musashi RNA Binding Protein 2) • NFKBIE (NFKB Inhibitor Epsilon) • SOX11 (SRY-Box Transcription Factor 11) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
    |
    TP53 mutation • MYC rearrangement
    1year
    SP140 represses specific loci by recruiting polycomb repressive complex 2 and NuRD complex. (PubMed, Nucleic Acids Res)
    In this work, we have applied a multi-omics approach (i.e. interactomics, ChIP-seq and proteomics) in two Burkitt lymphoma cell lines to identify both interactors and target genes of endogenous SP140. We found that SP140 interacts with the PRC2 and NuRD complexes, and we showed that these interactions are functional as SP140 directs H3K27me3 deposition and NuRD binding on a set of target genes implicated in cellular growth and leukemia progression.
    Journal
    |
    SP140 (SP140 Nuclear Body Protein)
    1year
    Machine learning-based identification of histone deacetylase-associated prognostic factors and prognostic modeling for low-grade glioma. (PubMed, Discov Oncol)
    We developed an HDAC-related four-gene prognostic model that correlates with survival, immune landscape, and therapeutic response in LGG patients. This model may guide personalized treatment strategies and improve prognostic accuracy, warranting further validation in clinical settings.
    Journal • IO biomarker • Epigenetic controller • Machine learning
    |
    SP140 (SP140 Nuclear Body Protein) • SIRT1 (Sirtuin 1)
    over1year
    Stratifying osteosarcoma patients using an epigenetic modification-related prognostic signature: implications for immunotherapy and chemotherapy selection. (PubMed, Transl Cancer Res)
    Drug sensitivity analysis revealed the low-risk group had increased sensitivity to cisplatin, a first-line OS chemotherapy. Our study successfully established an efficient EMRPS and nomogram, highlighting their potential as novel prognostic markers and indicators for selecting appropriate immunotherapy and chemotherapy candidates in OS treatment.
    Journal • IO biomarker
    |
    SP140 (SP140 Nuclear Body Protein) • HDAC4 (Histone Deacetylase 4) • SIRT7 (Sirtuin 7)
    |
    cisplatin
    over1year
    Gene mutations in newly diagnosed multiple myeloma patients detected by next-generation sequencing technology. (PubMed, Cancer Pathog Ther)
    The International Staging System (ISS) Stage III correlated with gene mutations in the NK-κB pathway while Revised ISS (R-ISS) Stage III correlated with the DNA damage repair pathway. There are various gene mutations in NDMM patients, mainly RAS/MAPK and NF-κB pathway gene pathways.
    Journal • Next-generation sequencing
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • CCND1 (Cyclin D1) • SP140 (SP140 Nuclear Body Protein) • SDC1 (Syndecan 1) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • KLHL6 (Kelch Like Family Member 6) • EGR1 (Early Growth Response 1)
    almost2years
    An endogenous retrovirus regulates tumor-specific expression of the immune transcriptional regulator SP140. (PubMed, Hum Mol Genet)
    In a fibrosarcoma cell line, silencing the cancer-specific ERV promoter of SP140 resulted in increased sensitivity to interferon-mediated cytotoxicity and dysregulation of multiple genes. Our findings implicate aberrant ERV-mediated SP140 expression as a novel mechanism contributing to immune gene dysregulation in a wide range of cancer cells.
    Journal
    |
    SP140 (SP140 Nuclear Body Protein)
    almost2years
    SP140 inhibitor suppressing TRIM22 expression regulates glioma progress through PI3K/AKT signaling pathway. (PubMed, Brain Behav)
    SP140-based nomogram proved to be a practical tool for predicting the survival of glioma patients. SP140 inhibitor could suppress glioma progress via TRIM22/PI3K/AKT signaling pathway.
    Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1) • SP140 (SP140 Nuclear Body Protein)
    2years
    A CIC-related-epigenetic factors-based model associated with prediction, the tumor microenvironment and drug sensitivity in osteosarcoma. (PubMed, Sci Rep)
    The risk score showed a strong correlation with the tumor microenvironment, drug sensitivity and many immune checkpoints. In summary, our study sheds a new light on the CIC-related epigenetic modulation mechanism of osteosarcoma and helps search for potential drugs for osteosarcoma treatment.
    Journal • IO biomarker
    |
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SP140 (SP140 Nuclear Body Protein) • CHD2 (Chromodomain Helicase DNA Binding Protein 2) • SFMBT2 (Scm Like With Four Mbt Domains 2)
    2years
    Unraveling neoantigen-associated genes in bladder cancer: An in-depth analysis employing 101 machine learning algorithms. (PubMed, Environ Toxicol)
    Additionally, consensus clustering analysis and immune infiltration analysis were performed on bulk sequencing datasets and immunotherapy cohorts. These analyses yield valuable insights into the role of neoantigens in BLCA, guiding future research endeavors.
    Journal • Machine learning
    |
    ACTA2 (Actin Alpha 2 Smooth Muscle) • SP140 (SP140 Nuclear Body Protein) • CD3G (CD3 Gamma Subunit Of T-Cell Receptor Complex) • PDIA6 (Protein Disulfide Isomerase Family A Member 6)
    over2years
    Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy. (PubMed, Am J Hematol)
    We observed enrichment of genetic aberrations of DNA damage response pathway (TP53 and CDKN2A/B), and a significant increase in MCL heterogeneity. We identified LRP1B inactivation as a new potential driver of MCL relapse.
    Journal • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • ATM (ATM serine/threonine kinase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • LRP1B (LDL Receptor Related Protein 1B) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • SP140 (SP140 Nuclear Body Protein)
    |
    TP53 mutation • TMB-H • PIK3CA mutation • CDKN2A deletion • LRP1B mutation • PIK3CA amplification